Skip to content
Vanta Bioscience logo

Vanta Bioscience

540729 BSE
Price unavailable

Vanta Bioscience (VANTABIO) share price was ₹20.40 at the 16 Oct 2026 close; market capitalisation ₹14.50 Cr; sector Healthcare. The share price fell 20.2% over the year to 16 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue was ₹1.51 Cr, against ₹0.33 Cr a year earlier and net profit was ₹1.93 Cr, against −₹1.37 Cr a year earlier (compared with Mar 2025). Promoters held 72.81% of Vanta Bioscience in Sep 2026, unchanged from Mar 2026.

Close 16 Oct 2026 ₹20.40 −1.26 −5.82% 1Y

Key Fundamentals

SMEHealthcare ServicesHealthcare
Market Cap
₹14.50 Cr
EBITDA
₹1.02 Cr
Return on Equity
-351.27%
Debt to Equity
1.8
Book Value
₹29.77
EPS (TTM)
−₹3.90
52W High
₹29.00
52W Low
₹14.71

Price-based figures as of 16 Oct 2026, 15:30 IST · TTM

Peer Comparison

Healthcare › Healthcare Technology › Healthcare Research, Analytics & Technology

₹407.0574.1416,431 Cr3.380.34%6.54%8.35%3,613 Cr221 Cr
₹597.2535.8514,392 Cr4.590.38%12.78%15.40%3,892 Cr401 Cr
₹265.00—7,488 Cr10.940.00%-46.73%-45.62%30 Cr-353 Cr
₹514.8028.842,301 Cr5.040.39%12.83%16.36%336 Cr80 Cr
₹119.238.96530 Cr1.260.47%9.14%11.73%441 Cr49 Cr
₹10.7012.30158 Cr5.100.00%13.73%15.37%100 Cr13 Cr
Vanta Bioscience (this company)
——15 Cr0.690.00%-351.27%-14.43%9 Cr-4 Cr
Median 7 companies₹336.0328.842,301 Cr4.590.34%9.14%11.73%336 Cr49 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100. How it works →

No Tapetide Score has been computed for this stock yet.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Stock is trading at 0.69 times its book value

Weaknesses

6
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -28.6% over past five years.
  • Company has a low return on equity of -15.6% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 513 days.
  • Working capital days have increased from -636 days to 435 days

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

Bearish

Bearish
12
Neutral
7
Bullish
0

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-13.33% higher than 3Y

change over 1 year

Net Income Growth
-100% lower than 3Y

change over 1 year

Cash Flow Change
-190%

change over 1 year

EBITDA Margin Change
-126%

change over 1 year Operating margin 91.39% · Mar 2026

Quarterly Results

Particulars Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
6.81
5.28
4.76
5.38
4.31
2.82
3.45
6.18
3.55
1.03
0.33
0.3
1.51
Expenses
4.61
3.5
2.58
3.89
2.33
3.37
5.3
4.12
4.3
1.42
2.01
0.67
0.13
Operating Profit
2.2
1.78
2.18
1.49
1.98
-0.55
-1.85
2.06
-0.75
-0.39
-1.68
-0.37
1.38
OPM %
32.31%
33.71%
45.8%
27.7%
45.94%
-19.5%
-53.62%
33.33%
-21.13%
-37.86%
-509.09%
-123.33%
91.39%
Other Income
0.11
0
0.03
0.02
0.4
0.01
0.68
0.03
0.08
0.04
0.04
0
0.16
Interest
0.98
1.01
1.13
1.14
1.2
2.48
3.4
2.85
2.9
2.14
-0.06
0.88
-0.11
Depreciation
0.78
0.61
0.65
0.66
0.66
1.31
1.36
1.54
2.95
1.69
-0.17
0.61
-0.23
PBT
0.55
0.16
0.43
-0.29
0.52
-4.33
-5.93
-2.3
-6.52
-4.18
-1.41
-1.86
1.88
Tax %
16.36%
68.75%
9.3%
-106.9%
13.46%
2.08%
1.52%
-0.87%
-3.07%
-1.2%
-2.13%
-2.69%
-2.66%
Net Profit
0.46
0.06
0.39
0.02
0.07
-2.56
-3.92
-0.54
-1.78
-2.07
-1.37
-1.82
1.93
EPS (₹)
0.73
0.1
0.62
0.03
0.11
-4.06
-6.21
-0.86
-2.82
-3.28
-2.17
-2.56
2.71
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
12.08
13.75
9.82
9.4
5.83
9.72
1.96
1.82
Expenses
8.81
9.38
5.87
5.93
8.22
8.41
6.21
0.8
Operating Profit
3.27
4.37
3.95
3.47
-2.39
1.31
-4.25
1.02
OPM %
27.07%
31.78%
40.22%
36.91%
-40.99%
13.48%
-216.84%
56.04%
Other Income
0.23
0.11
0.03
0.42
0.69
0.11
0.11
0.16
Interest
1.69
1.95
2.14
2.35
5.89
5.75
4.07
0.78
Depreciation
0.71
1.19
1.25
1.32
2.67
4.5
4.42
0.39
PBT
1.1
1.34
0.59
0.22
-10.26
-8.83
-12.63
0.01
Tax %
36.36%
24.63%
23.73%
40.91%
1.75%
-2.49%
5.23%
-900%
Net Profit
0.7
1.01
0.45
0.14
-10.44
-8.61
-13.29
0.11
EPS (₹)
1.11
1.58
0.71
0.14
-10.27
-3.68
-7.56
0.15
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6.31
6.31
6.31
6.31
6.31
6.31
6.31
7.11
Reserves
15.94
17.16
17.61
17.7
11.2
8.89
4.11
14.06
Borrowings
13.25
17.37
35.97
44.86
57.16
60.96
70.09
38.08
Other Liabilities
3.51
7.74
9.74
12.53
10.04
9.24
5.37
6.85
Total Liabilities
39.01
48.58
69.63
81.4
84.71
85.4
85.88
66.1
Fixed Assets
17.9
20.76
29.39
36.12
57.22
54.15
55.5
48.08
CWIP
3.7
7
19.34
28.47
10.6
12.53
13.47
0
Investments
1.95
0
0
0
0
0
0
3
Other Assets
15.46
20.82
20.9
16.81
16.89
18.72
16.91
15.02
Total Assets
39.01
48.58
69.63
81.4
84.71
85.4
85.88
66.1
Figures in ₹ Crores

Cash Flow

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-1.04
2.34
6.97
5.28
-0.63
2.68
-2.41
-5.22
Investing
-5.73
-7.59
-22.3
-17.24
-5.91
-3.31
-6.69
-6.87
Financing
9.94
2.17
17.78
9.53
6.41
0.69
9.16
12.08
Net Cash Flow
3.18
-3.07
2.46
-2.43
-0.13
0.06
0.06
-0.01
Free Cash Flow
-3.52
-5.01
-15.23
-11.9
-6.54
-0.63
-9.1
-12.09
CFO/OP
-32
54
176
152
26
205
57
-512
Figures in ₹ Crores

Ratios

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
47.14
36.9
74.71
43.88
123
118
466
513
Inventory Days
—
—
—
—
—
—
2,400
—
Days Payable
—
—
—
—
—
—
1,821
—
Cash Conversion Cycle
47.14
36.9
74.71
43.88
123
118
1,044
513
Working Capital Days
261
260
91.06
-135
-163
-217
-2,127
435
ROCE %
—
8.35%
5.21%
3.77%
-5.82%
-4.16%
-11.58%
1.19%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vanta Bioscience insights

57 extracted metrics + investor summaries across FY17–FY26.

Shareholding Pattern

Promot.72.81%Others2.84%Public24.36%As ofSep 2026

Documents

Frequently Asked Questions about Vanta Bioscience

What does Vanta Bioscience Ltd do?
Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation. [1]
Where is Vanta Bioscience Ltd (VANTABIO) listed?
Vanta Bioscience Ltd trades under code 540729 on the BSE.
Which sector does Vanta Bioscience Ltd belong to?
Vanta Bioscience Ltd is classified under the Healthcare sector, in the Healthcare Technology industry.
What is the market capitalisation of Vanta Bioscience Ltd?
Vanta Bioscience Ltd has a market capitalisation of ₹14.5 Cr as of 16 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Vanta Bioscience Ltd?
Over the last 52 weeks Vanta Bioscience Ltd has traded between ₹14.71 and ₹29 as of 16 Oct 2026.
What is the Return on Equity (ROE) of Vanta Bioscience Ltd?
Vanta Bioscience Ltd reported a return on equity of -351.27%. Its debt-to-equity ratio is 1.80.

Company Information

Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation. [1]

Website vantabio.com
Listed 2017-10-06
Face Value ₹ 10
Shares Outstanding 71,07,843

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540729.md for Vanta Bioscience Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More